Can I read Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study on EtoBox?

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study by Nizar M Tannir; Daniel C Cho; Adi Diab; Mario Sznol; Mehmet A Bilen; Arjun V Balar; Giovanni Grignani; Erika Puente; Lily Tang; David Chien; Ute Hoch; Arkopal Choudhury; Danni Yu; Sue L Currie; Mary A Tagliaferri; Jonathan Zalevsky; Arlene O Siefker-Radtke; Michael E Hurwitz is a Medicine article available to read on EtoBox.

What is Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study about?

## Background Immune checkpoint inhibitor-based combinations have expanded the treatment options for patients with renal cell carcinoma (RCC); however, tolerability remains challenging. The aim of this study was to evaluate the safety and efficacy of the immunostimulatory interleukin-2 cytokine prodrug bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) as first-line therapy in patients with advanced clear-cell RCC. ## Methods This was an open-label multicohort, multicenter, single-arm phase 1/2 study; here, we report results from the phase 1/2 first-line RCC cohort (N=49). Patients received BEMPEG 0.006 mg/kg plus NIVO 360 mg intravenously every 3 weeks. The primary objectives were safety and objective response rate (ORR; patients with measurable disease at baseline and at least one postbaseline tumor response assessment). Secondary objectives included overall survival (OS) and progression-free survival (PFS). Exploratory biomarker analyses: association between baseline biomarkers and ORR. ## Results At a median follow-up of 32.7 months, the ORR was 34.7% (17/49 patients); 3/49 patients (6.1%) had a complete response. Of the 17 patients with response, 14 remained in response for >6 m

Who reads Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study?

Author

Nizar M Tannir; Daniel C Cho; Adi Diab; Mario Sznol; Mehmet A Bilen; Arjun V Balar; Giovanni Grignani; Erika Puente; Lily Tang; David Chien; Ute Hoch; Arkopal Choudhury; Danni Yu; Sue L Currie; Mary A Tagliaferri; Jonathan Zalevsky; Arlene O Siefker-Radtke; Michael E Hurwitz

Publisher

BMJ Publishing Group

Published

2022

Language

EN

Field

Medicine (Health Sciences)